Tenaya Therapeutics, Inc. (TNYA)Healthcare | Biotechnology | South San Francisco, United States | NasdaqCM
0.69 USD
-0.01
(-0.734%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.70 +0.01 (0.797%) ⇧ (Aug. 28, 2026, 7:31 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:05 a.m. EDT
Tenaya Therapeutics presents a classic biotech value trap where aggressive analyst targets and recent clinical data headlines mask a fundamentally broken business model. The company is hemorrhaging cash, with operating cash flow and free cash flow both deeply negative, and the balance sheet is barely holding on despite a massive cash burn rate. Fundamentally, the stock is a disaster: it has lost over 95% of its value over the last four years, with the trailing twelve months showing a catastrophic -58% decline. The negative earnings per share and return on equity confirm that the core business is not generating value. While the analyst consensus is 'strong buy' with a $3.20 target, this ignores the reality that the company is burning through its limited war chest without a proven path to profitability. The options market reflects this fragility; there is almost no insurance being bought, suggesting speculators are chasing a binary event rather than investing in a turnaround. For a long-term investor, the combination of deteriorating fundamentals, a multi-year price collapse, and no dividend safety net makes this a dangerous hold. The short-term outlook remains bearish due to the high beta and lack of institutional support, though the speculative call flow hints at a potential volatility spike if a major trial result is released. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.048231 |
| MSTL | 0.076358 |
| AutoTheta | 0.080501 |
| AutoETS | 0.080674 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 6.55 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.689 |
| Excess Kurtosis | -0.18 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.689 |
| Revenue per Share | 0.007 |
| Market Cap | 154,741,136 |
| Forward P/E | -1.76 |
| Beta | 2.79 |
| Website | https://www.tenayatherapeutics.com |
As of Aug. 22, 2026, 4:05 a.m. EDT: Options activity shows a distinct lack of protective put writing, with zero open interest in OTM puts for the nearest expiration and negligible volume overall. Call positioning is heavily skewed toward out-of-the-money strikes ($1.00, $1.50, $2.00), indicating speculative bets on a significant upside move rather than hedging against downside risk. This asymmetry suggests traders are positioning for a catalyst-driven rally while ignoring the immediate downside tail risk.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3564815 |
| Address1 | 171 Oyster Point Boulevard |
| Address2 | Suite 500 |
| All Time High | 32.0 |
| All Time Low | 0.36 |
| Ask | 0.8988 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 2,063,020 |
| Average Daily Volume3 Month | 2,460,125 |
| Average Volume | 2,460,125 |
| Average Volume10Days | 2,063,020 |
| Beta | 2.791 |
| Bid | 0.66 |
| Bid Size | 1 |
| Book Value | 0.489 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.6901 |
| Current Ratio | 4.522 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.7036 |
| Day Low | 0.6869 |
| Debt To Equity | 5.689 |
| Display Name | Tenaya Therapeutics |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda | -75,524,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.067 |
| Enterprise To Revenue | 60.378 |
| Enterprise Value | 80,605,128 |
| Eps Current Year | -0.46 |
| Eps Forward | -0.392 |
| Eps Trailing Twelve Months | -0.5 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.7608 |
| Fifty Day Average Change | -0.07069999 |
| Fifty Day Average Change Percent | -0.092928484 |
| Fifty Two Week Change Percent | -35.648148 |
| Fifty Two Week High | 2.35 |
| Fifty Two Week High Change | -1.6599 |
| Fifty Two Week High Change Percent | -0.70634043 |
| Fifty Two Week Low | 0.532 |
| Fifty Two Week Low Change | 0.15810001 |
| Fifty Two Week Low Change Percent | 0.29718047 |
| Fifty Two Week Range | 0.532 - 2.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,651,800,000 |
| Float Shares | 211,682,101 |
| Forward Eps | -0.392 |
| Forward P E | -1.7604593 |
| Free Cashflow | -32,600,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 70 |
| Fullday Change | -0.00510001 |
| Fullday Change Percent | -0.733604 |
| Fullday Price | 0.6956 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 1,335,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00438 |
| Held Percent Institutions | 0.48851 |
| Implied Shares Outstanding | 224,230,012 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. |
| Long Name | Tenaya Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 154,741,136 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_409125654 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -103,115,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 156,972,219 |
| Number Of Analyst Opinions | 5 |
| Open | 0.7008 |
| Operating Cashflow | -52,325,000 |
| Operating Margins | -18.82793 |
| Payout Ratio | 0.0 |
| Phone | 650 825 6990 |
| Post Market Change | 0.005499959 |
| Post Market Change Percent | 0.79697996 |
| Post Market Price | 0.6956 |
| Post Market Time | 1,787,959,872 |
| Previous Close | 0.6952 |
| Price Eps Current Year | -1.5002174 |
| Price Hint | 4 |
| Price To Book | 1.4112475 |
| Price To Sales Trailing12 Months | 115.910965 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.125 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.28571 |
| Region | US |
| Regular Market Change | -0.00510001 |
| Regular Market Change Percent | -0.733604 |
| Regular Market Day High | 0.7036 |
| Regular Market Day Low | 0.6869 |
| Regular Market Day Range | 0.6869 - 0.7036 |
| Regular Market Open | 0.7008 |
| Regular Market Previous Close | 0.6952 |
| Regular Market Price | 0.6901 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,095,765 |
| Return On Assets | -0.47912997 |
| Return On Equity | -1.21859 |
| Revenue Per Share | 0.007 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 224,230,012 |
| Shares Percent Shares Out | 0.0941 |
| Shares Short | 21,100,721 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 24,919,430 |
| Short Name | Tenaya Therapeutics, Inc. |
| Short Percent Of Float | 0.121199995 |
| Short Ratio | 11.33 |
| Source Interval | 15 |
| State | CA |
| Symbol | TNYA |
| Target High Price | 5.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 3.2 |
| Target Median Price | 3.0 |
| Total Cash | 78,085,000 |
| Total Cash Per Share | 0.348 |
| Total Debt | 3,949,000 |
| Total Revenue | 1,335,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.5 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.818865 |
| Two Hundred Day Average Change | -0.12876499 |
| Two Hundred Day Average Change Percent | -0.15724812 |
| Type Disp | Equity |
| Volume | 1,095,765 |
| Website | https://www.tenayatherapeutics.com |
| Zip | 94,080 |